Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.40 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642001 | 1.00 | CYP19A1 (0.41) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL1641999 | 1.00 | CYP19A1 (0.41) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL1643613 | 0.77 | LMNA (0.46) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL29636596 | 0.77 | LMNA (0.46) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL29362469 | 0.77 | LMNA (0.46) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL1644169 | 0.73 | KMT2A (0.51) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL29665865 | 0.73 | KMT2A (0.51) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL27585725 | 0.70 | TSHR (0.58) | KMT2AMAPTMEN1POLBPLIN1 | |
| SCHEMBL28927886 | 0.70 | KMT2A (0.51) | CYP19A1KMT2AMAPTMEN1POLB | |
| SCHEMBL28766154 | 0.70 | KMT2A (0.51) | CYP19A1KMT2AMAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459305-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20190218191-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20180346428-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2018-12-06 | — | — | US | disclosed |
| US-9868706-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9382214-B2 | Processes for the preparation of uracil derivatives | Neurocine Biosciences, Inc. (US) | 2016-07-05 | — | — | US | disclosed |
| US-8765948-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2011-04-28 | — | — | US | disclosed |
| WO-2009062087-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | CYP19A1 54/4885KMT2A 2736/4885MAPT 3982/4885 |
| US-20190218191-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | CYP19A1 54/4885KMT2A 2736/4885MAPT 3982/4885 |
| US-20180346428-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | CYP19A1 54/4885KMT2A 2736/4885MAPT 3982/4885 |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | CYP19A1 54/4885KMT2A 2736/4885MAPT 3982/4885 |
| US-11459305-B2 | Processes for the preparation of uracil derivatives | GNRHR, FSHR, GHRHR | CYP19A1 54/4885KMT2A 2736/4885MAPT 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.